ESR1 and breast cancer: Treatment of the ER+ breast cancer cell line MCF7 with IL-6 induces an EMT phenotype in vitro, resulting in the upregulation of key EMT genes such as N-cadherin, Snail, Vimentin and Twist, as well as, the loss of E-cadherin expression [85].